Arrowhead Pharmaceuticals

Update in progress

ARWR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Arrowhead Pharmaceuticals, Inc. develops RNA interference therapies for hard‑to‑treat diseases in the United States. Its pipeline includes Plozasiran (APO C‑III) in Phase 3, Zodasiran (ANGPTL3) in Phase 3, ARO‑DIMER‑PA (dual RNAi) in Phase 1/2a, and ARO‑PNPLA3 in Phase 1. It also has ARO‑INHBE, ARO‑ALK7, ARO‑RAGE, ARO‑MAPT, ARO‑C3, and ARO‑CFB in various early phases. The company collaborates with GSK, Takeda, Amgen, and Sarepta. Founded 2003, Pasadena, California.

Company score

Sentiment: 2.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.37; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.51; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.52; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.38; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive